Filing Flows

Filing Flows › 8-K events › Abeona Therapeutics

Abeona Therapeutics: completion of an acquisition or disposition of assets

Form 8-K filed Nov 9, 2026 · items 1.01, 2.01, 3.02, 7.01

FDA decisionsAbeona Therapeutics ® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement

What the filing says

The information contained above in Item 1.01 is hereby incorporated by reference into this Item 2.01.

ScaleThe filing names $30.0M: about 66% of Abeona Therapeutics' annual revenue ($45.5M, four times the latest quarter).

Read the filing on SEC EDGAR →

What usually followsAcross 23,535 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.01: +0.1% next session across 2,672. Item 3.02: +0.2% next session across 2,752. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Item 2.01 — Completion of an acquisition or disposition of assets. Completing an acquisition or a sale changes the company’s size and mix from this quarter on; the price paid and how it was financed are in the filing.

Abeona Therapeutics at a glance

Latest quarterQ2 2026
Revenue$11.4M
Revenue Y/Y28×
Operating margin-120.0%
IndustryPharmaceutical Preparations

Abeona Therapeutics, Q2 2026: revenue $11.4M (28× year over year), operating margin -120.0%. The chart follows the revenue to costs, profit and cash.

Abeona Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →

Abeona Therapeutics’s other material 8-Ks

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.